Evidence map›Paper›PMID 40302388›Full record

ArticleJournal of Parkinson's disease2025

Dementia risk prediction in early Parkinson's disease: Validation and genetic integration of the Montreal Parkinson risk of dementia scale (MoPaRDS).

Aleksandra A Szwedo, Ingvild Dalen, Rachael A Lawson, Alison J Yarnall, Kenn Freddy Pedersen, Angus D Macleod, Carl E Counsell, David Bäckström, Lars Forsgren, Marta Camacho and 5 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aleksandra A SzwedoThe Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.ORCID 0000-0001-6987-9904
Ingvild DalenDepartment of Research, Section of Biostatistics, Stavanger University Hospital, Stavanger, Norway.ORCID 0000-0002-8160-3211
Rachael A LawsonTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0003-2608-8285
Alison J YarnallTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-3126-9163
Kenn Freddy PedersenThe Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Angus D MacleodInstitute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.ORCID 0000-0002-6284-4239
Carl E CounsellInstitute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.ORCID 0000-0001-6622-7839
David BäckströmDepartment of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.ORCID 0000-0002-4417-2475
Lars ForsgrenDepartment of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.ORCID 0000-0002-4051-4917
Marta CamachoDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID 0000-0002-1490-5703
Caroline H Williams-GrayDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID 0000-0002-2648-9743
Ole-Bjørn TysnesDepartment of Neurology, Haukeland University Hospital, University of Bergen, Bergen, Norway.
Guido AlvesThe Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.ORCID 0000-0003-0630-2870
Jodi Maple-GrødemThe Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.ORCID 0000-0001-7142-0078
Parkinson's Incidence Cohorts Collaboration

Funding

Wellcome Trust
6 · The paper itself

Abstract

BackgroundPrediction models for dementia in Parkinson disease (PD) are needed to better identify high-risk patients, but existing risk models often lack validation in early-stage PD, when prognosis is most challenging.ObjectiveThis study aims to validate the Montreal Parkinson Risk of Dementia Scale (MoPaRDS) in six population-based cohorts of newly diagnosed PD and to evaluate if incorporating genetic factors (

Indexed as

DementiaMental Status and Dementia TestsParkinson DiseaseAgedAged, 80 and overApolipoprotein E4FemaleGlucosylceramidaseHumansMaleMiddle AgedRisk AssessmentApolipoprotein E4GBA protein, humanGlucosylceramidasecognitive dysfunctiondementiageneticParkinson's diseaserisk factors

Identifiers

PMID40302388
PMCPMC13347466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.